PRODUCT INFORMATION
LIVOSTIN®
Eye Drops and Nasal Spray

NAME OF MEDICINE
Levocabastine hydrochloride

DESCRIPTION
Levocabastine, (\(-\)[3S-[1(cis), 3 alpha, 4 beta]-1-[4-cyano-4-(4-fluorophenyl) cyclohexyl]-3-methyl-4-phenyl-4-piperidine-carboxylic acid monohydrochloride is a highly selective histamine H\(_1\)-antagonist for topical use.

Levocabastine hydrochloride is a white powder, insoluble in water except at higher pH and only fairly soluble in other solvents such as acetone.

CAS-79547-78-7  \(\text{C}_{26}\text{H}_{30}\text{FN}_{2}\text{O}_{2}\cdot\text{HCl}\)  MW: 456.99

LIVOSTIN® eye drops contain levocabastine hydrochloride equivalent to levocabastine 0.5 mg/mL as active ingredient, benzalkonium chloride and disodium edetate (both 0.15 mg/mL) as preservatives, and propylene glycol, polysorbate 80, sodium phosphate dibasic, sodium phosphate monobasic, hypromellose and water as inactive excipients in a sterile ophthalmic microsuspension (pH 6-8).

LIVOSTIN® nasal spray contains levocabastine hydrochloride equivalent to levocabastine 0.5 mg/mL as active ingredient, benzalkonium chloride and disodium edetate (both 0.15 mg/mL) as preservatives and propylene glycol, polysorbate 80, sodium phosphate dibasic, sodium phosphate monobasic, hypromellose and water as inactive excipients.

LIVOSTIN® nasal spray is available as a microsuspension (pH 6-8).

PHARMACOLOGY
Pharmacodynamics
LIVOSTIN® eye drops contain levocabastine, a potent, fast-acting and highly selective histamine H\(_1\)-antagonist with a sustained duration of action. After topical application to the eyes, it almost immediately and for several hours relieves the typical symptoms of allergic conjunctivitis (itching, redness, chemosis, eyelid swelling, tearing).

LIVOSTIN® nasal spray contains levocabastine, a potent, fast-acting and highly selective histamine H\(_1\)-antagonist with a sustained duration of action. After topical application to the nose, it almost immediately and for several hours relieves the typical symptoms of allergic rhinitis (sneezing, itchy nose, rhinorrhea).
Pharmacokinetics

After intranasal and ocular application, the absorption of levocabastine is incomplete with a systemic bioavailability ranging from 60 to 80% for the nasal spray and from 30 to 60% for the eye drops. However, as the amount of levocabastine applied intranasally and ocularly is small, the levocabastine plasma concentrations achieved are very low. Steady-state concentrations of levocabastine are attained within 7 to 10 days following multiple dosage and are predictable from single-dose pharmacokinetics.

Levocabastine undergoes minimal hepatic metabolism, i.e. ester glucuronidation, and is predominantly cleared by the kidneys. 70% of the parent drug is recovered unchanged in the urine, and 10% of the dose is excreted in the urine as the acylglucuronide of levocabastine. The remaining 20% is excreted unchanged in the faeces.

After single intravenous dosing, levocabastine is rapidly distributed over the tissues, and the terminal half-life is 33 h. The total steady-state volume of distribution is 82 L (1.14 L/kg) with a total plasma clearance of 30 mL/min.

Given the extremely low plasma concentrations after ocular application, a dose adjustment is unlikely to be required in patients with renal impairment receiving levocabastine eye drops. However, dose reduction should be considered in patients with renal disease during prolonged treatment with levocabastine nasal spray. As hepatic metabolism of levocabastine is negligible, dose adjustments in patients with impaired hepatic function should not be necessary.

The plasma protein binding of levocabastine is 55% with albumin being the main binding protein.

Special populations (1, 2)

Elderly

In the elderly, after multiple nasal administrations of 0.4mg levocabastine for 14 days, the terminal half-life of levocabastine was increased by 15% and the peak plasma level was increased by 26%.

Renal impairment

After a single oral dose of 0.5mg levocabastine in solution, the terminal half-life of levocabastine in moderate to severe renal impairment (Creatinine Clearance 10 – 50 mL/min) increased from 36 hours to 95 hours. Overall exposure to levocabastine based on AUC was increased by 56%.

INDICATIONS

Eye Drops: Symptomatic treatment of seasonal allergic conjunctivitis.

Nasal Spray: Symptomatic treatment of seasonal or perennial allergic rhinitis.

Clinical Studies

Clinical studies have shown that LIVOSTIN® eye drops and nasal spray are effective for the indications listed above. The duration of treatment with the eye drops alone was generally 2 - 4 weeks but lasted up to 3 months in two studies and 4 months in one study. Duration of treatment with the nasal spray alone was also generally 2 - 4 weeks, but lasted up to 10 weeks in some instances. The duration of treatment in studies using a combination of the eye drops and nasal spray was 8 weeks.

CONTRAINDICATIONS

Hypersensitivity to any of the ingredients.
PRECAUTIONS

Use with caution in the following circumstances

**Eye Drops:** As with all ophthalmic preparations containing benzalkonium chloride, patients are advised not to wear soft (hydrophilic) contact lenses while under treatment with LIVOSTIN® eye drops.

**Use in patients with renal impairment**

**Nasal Spray:** Limited data are available on the use of oral levocabastine. Caution should be exercised when administering LIVOSTIN® nasal spray to patients with renal impairment (refer to pharmacokinetics – renal impairment).

**Paediatric use**

No data on use in children less than six years of age are available.

**Carcinogenicity/mutagenicity**

In female mice, dietary administration of levocabastine for 20 months stimulated the development of pituitary adenomas and mammary adenocarcinomas. The no-effect dose level for the pituitary tumours was 3 mg/kg/day, but a no-effect dose level has not been established for the mammary tumours. In female rats, there was an equivocal increase in the incidence of mammary tumours at the highest dose level of 34 mg/kg/day administered in the diet for 24 months. There was no evidence of carcinogenic activity in male rats or mice. The mechanism of the carcinogenic effects of levocabastine in female mice (and possibly rats) may involve antagonism of dopamine D₂-receptors in the pituitary gland and subsequent elevation of serum prolactin levels.

**Use in pregnancy**

Pregnancy Category B3. In pregnant rats, levocabastine readily crossed the placental barrier and was distributed extensively in foetal tissues. Reproductive studies in mice and rats showed that levocabastine was embryolethal at oral doses greater than 40 mg/kg/day in both species, and teratogenic at oral doses greater than 40 mg/kg/day in mice and 20 mg/kg/day in rats. The main foetal malformations observed were open eyes in mice, and polydactyly, hydrocephalus, anophthalma/microphthalmia, hydronephrosis and arthrogryposis in rats. There are limited postmarketing data on the use of LIVOSTIN® eye drops or nasal spray in pregnant women. The risk for humans is unknown. Therefore, LIVOSTIN® eye drops and nasal spray should not be used during pregnancy.

**Use in lactation**

Based on determinations of levocabastine concentrations in saliva and breast milk in a nursing woman, who received a single oral dose of 0.5mg levocabastine, it is expected that approximately 0.6% of the total intranasally administered dose of levocabastine may be transferred to a nursing infant. However, due to the limited nature of the clinical and experimental data, it is recommended that LIVOSTIN® nasal spray or eye drops be avoided in breast-feeding mothers.

**Interactions with other drugs**

No interactions have been seen with LIVOSTIN® eye drops. With LIVOSTIN® nasal spray there were no reports of interaction with alcohol in clinical trials. In psychomotor performance studies there was no significant potentiation of the effects of alcohol on performance and subjective test measures with LIVOSTIN® nasal spray used at normal doses.

*Pharmacokinetic interactions*

The decongestant oxymetazoline may transiently reduce the absorption of nasal levocabastine.

Co-administration of the CYP3A4 inhibitors ketoconazole (200mg) and erythromycin (333mg) as a single dose had no impact on the pharmacokinetics of intranasal levocabastine.
Intranasal levocabastine did not change the pharmacokinetics of loratadine.

Instructions to the patient
Activities requiring alertness: In clinical trials there was no significant difference in the incidence of slowed patient reactions with LIVOSTIN® compared to placebo and active comparator drugs. LIVOSTIN®, therefore, would not be expected to interfere with the ability to drive a motor vehicle or operate machinery. Should drowsiness occur, caution is advised.

ADVERSE EFFECTS
Clinical Trial Data
Eye Drops:
The safety of LIVOSTIN® eye drops was evaluated in 508 subjects who participated in 4, placebo-controlled clinical trials and one open-label clinical trial. All adverse drug reactions (ADRs) reported by subjects in LIVOSTIN® eye drops clinical trials are presented in Table 1.

<table>
<thead>
<tr>
<th>MedDRA System Organ Class</th>
<th>LIVOSTIN® (n=508) %</th>
<th>Placebo (n=178) %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye Irritation</td>
<td>11.6</td>
<td>4.5</td>
</tr>
</tbody>
</table>

Nasal Spray:
The safety of LIVOSTIN® nasal spray was evaluated in 2328 subjects who participated in 12 double-blind, placebo-controlled clinical trials. Adverse drug reactions (ADRs) reported in ≥1% of subjects in these trials are presented in Table 2.

<table>
<thead>
<tr>
<th>MedDRA System Organ Class</th>
<th>LIVOSTIN® (n=2328) %</th>
<th>Placebo (n=1537) %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>1.3</td>
<td>1.2</td>
</tr>
<tr>
<td>General Disorders and Administrative Site Conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>2.1</td>
<td>0.9</td>
</tr>
<tr>
<td>Pain</td>
<td>1.2</td>
<td>0.9</td>
</tr>
<tr>
<td>Infections and Infestations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sinusitis</td>
<td>1.8</td>
<td>0.9</td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>10.1</td>
<td>11.9</td>
</tr>
<tr>
<td>Somnolence</td>
<td>2.1</td>
<td>0.8</td>
</tr>
<tr>
<td>Dizziness</td>
<td>1.3</td>
<td>0.9</td>
</tr>
<tr>
<td>Respiratory, Thoracic, and Mediastinal Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharyngolaryngeal pain</td>
<td>2.9</td>
<td>2.3</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>1.6</td>
<td>1.0</td>
</tr>
<tr>
<td>Cough</td>
<td>1.7</td>
<td>1.3</td>
</tr>
</tbody>
</table>
Additional ADRs reported for <1% of LIVOSTIN® Nasal Spray treated subjects in the 12 clinical trials are presented in Table 2.

### Table 2: Adverse Drug Reactions Reported by <1% LIVOSTIN® Nasal Spray Treated Subjects in 12 Double-Blind, Placebo-Controlled Clinical Trials

**MedDRA System Organ Class**

**MedDRA PT**

**General Disorders and Administrative Site Conditions**

- Application site irritation
- Application site pain
- Application site dryness
- Application site burn
- Application site discomfort

**Respiratory, Thoracic, and Mediastinal Disorders**

- Nasal discomfort
- Nasal congestion

**Postmarketing Data**

Additional adverse drug reactions first identified during postmarketing experience with LIVOSTIN® eye drops and nasal spray are included in Table 3 (nasal spray) and Table 4 (eye drops). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Therefore, the frequencies are provided according to the following convention (3,4):

- **Very Common**: ≥ 1/10
- **Common**: ≥ 1/100 and < 1/10
- **Uncommon**: ≥ 1/1000 and < 1/100
- **Rare**: ≥ 1/10000 and < 1/1000
- **Very rare**: ≥ 1/10000, including isolated reports

In the tables below ADR’s are presented by frequency category based on incidence in clinical trials or epidemiology studies when known.

### Table 3: Adverse Drug Reactions Identified During Postmarketing Experience with LIVOSTIN® Eye Drops by Frequency Category Estimated from Spontaneous Reporting Rates

<table>
<thead>
<tr>
<th>Cardiac Disorders</th>
<th>Palpitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye Disorders</td>
<td>Eye pain, Conjunctivitis, Eyelid oedema, Eye swelling, Blepharitis, Ocular hyperaemia, Vision blurred</td>
</tr>
<tr>
<td>General Disorders and Administrative Site Conditions</td>
<td>Application site reaction including eye burning sensation, eye redness, eye pain, eye swelling, eye itching, watery eyes and vision blurred.</td>
</tr>
<tr>
<td>Immune System Disorders</td>
<td>Anaphylaxis, Angioneurotic oedema, Hypersensitivity</td>
</tr>
</tbody>
</table>

In the tables below ADR’s are presented by frequency category based on incidence in clinical trials or epidemiology studies when known.
Skin and Subcutaneous Tissue Disorders
Very Rare

Nervous System Disorders
Headache

<table>
<thead>
<tr>
<th>Cardiac Disorders</th>
<th>Very Rare</th>
<th>Palpitations, Tachycardia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye Disorders</td>
<td>Very Rare</td>
<td>Eyelid Oedema</td>
</tr>
<tr>
<td>General Disorders and Administrative Site Conditions</td>
<td>Very Rare</td>
<td>Malaise</td>
</tr>
<tr>
<td>Immune System Disorders</td>
<td>Very Rare</td>
<td>Anaphylaxis, Hypersensitivity</td>
</tr>
<tr>
<td>Respiratory, Thoracic, and Mediastinal Disorders</td>
<td>Very Rare</td>
<td>Bronchospasm, Dyspnoea, Nasal oedema</td>
</tr>
</tbody>
</table>

**Table 4: Adverse Drug Reactions Identified During Postmarketing Experience with LIVOSTIN® Nasal Spray by Frequency Category Estimated from Spontaneous Reporting Rates**

**DOSAGE AND ADMINISTRATION**

As LIVOSTIN® eye drops and nasal spray are available as a microsuspension, the bottle should be shaken before each application.

**Eye Drops:**

Adults and children 6 years of age and over: the usual dose is one drop of LIVOSTIN® eye drops per eye, twice daily. If necessary, the dose may be increased to one drop 3 to 4 times daily. The bottle should be well shaken before use. The duration of treatment should be limited to 8 weeks.

Systemic absorption of levocabastine is very low. However, the systemic absorption of drugs from ophthalmic solutions can be minimised by pressure on the tear duct immediately after application.

LIVOSTIN® eye drops should be used within one month of first opening of the bottle. Patients should be instructed to take appropriate measures to avoid contamination of the container.

**Nasal Spray:**

Adults and children 6 years of age and over: the usual dose is two sprays of LIVOSTIN® nasal spray per nostril, twice daily. If necessary, the dose may be increased to two sprays 3 to 4 times daily. The duration of treatment should be limited to 8 weeks.

Patients should be instructed to clear the nasal passages prior to administering the spray and to inhale through the nose during spraying. Before using the pump delivery system for the first time, the pump reservoir should be filled by priming until a fine spray is delivered.
OVERDOSE
There has been no experience with overdose of LIVOSTIN® eye drops or nasal spray to date. After accidental intake of the contents of the bottle, sedation may occur. In case of overdose, the patient should be advised to drink plenty of water in order to accelerate the renal elimination of levocabastine.

PRESENTATION
LIVOSTIN® eye drops: 4 mL in 5 mL bottle.
LIVOSTIN® nasal spray: 10 mL in 15 mL bottle.

Storage
LIVOSTIN® eye drops and nasal spray should be stored below 25°C.

SPONSOR
Johnson & Johnson Pacific
45 Jones Street, Ultimo
NSW 2007
Australia

Date of TGA approval: 20 April 17